Assertio Therapeutics Announces Favorable NUCYNTA® Patent Ruling
With the Court’s ruling, the company expects market exclusivity until
The Federal Circuit affirmed the District Court’s ruling with regard to U.S. patent No. 8,536,130 (the ‘130 Patent), which upheld the validity of the ‘130 Patent but found that two of the three ANDA filers do not infringe the patent. The ‘130 Patent covers NUCYNTA® ER until
The defendants in the appeal of the District Court’s ruling in the patent litigation included
(1) Patent expiration dates reflect the addition of six months of pediatric patent term extension Assertio anticipates securing from the
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks related to regulatory approval and clinical development of long-acting cosyntropin, expectations regarding royalties to be received based on sales of NUCYNTA and NUCYNTA ER, expectations regarding potential business opportunities and other risks outlined in the Company's public filings with the
Investor and Media Contact:
SVP, Investor Relations and Corporate Communications
Source: Assertio Therapeutics, Inc.
Minimum 15 minutes delayed.